- Home
- NSTS vs DXR Comparison
NSTS vs DXR Comparison
Compare NSTS & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | DXR |
|---|---|---|
| Founded | 1921 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.8M | 69.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NSTS | DXR |
|---|---|---|
| Price | $12.53 | $12.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 3.8K | ★ 7.4K |
| Earning Date | 11-13-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $9,762,000.00 | $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $35.27 |
| Revenue Growth | ★ 57.78 | N/A |
| 52 Week Low | $10.72 | $6.55 |
| 52 Week High | $13.32 | $14.76 |
Technical Indicators
Market Signals| Indicator | NSTS | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 38.98 |
| Support Level | $12.52 | $11.87 |
| Resistance Level | $12.59 | $12.90 |
| Average True Range (ATR) | 0.07 | 0.63 |
| MACD | -0.05 | -0.22 |
| Stochastic Oscillator | 2.08 | 12.00 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.